期刊文献+

弥漫性大B细胞淋巴瘤变型的病理及免疫表型分析

Analysis of Histopathologic Features and Immunophenotype in Morphologic Variants of Diffuse Large B-cell Lymphoma
下载PDF
导出
摘要 目的:探究弥漫性大B细胞淋巴瘤(DLBCL)变型的组织学特点及免疫表型。方法:收集108例DLBCL,总结其临床资料和组织病理学特点,进行组织微阵列免疫组化检测CD10、bcl-6的表达。结果:中心母细胞型(CB)为89.8%,免疫母细胞型(IB)2.8%,间变性大B细胞型(ALCL)1.9%,富于T细胞的B细胞型(TCRBCL)1.9%,其它变型3.7%;23.1%见较多背景反应细胞,41.7%伴有纤维化基质,21.3%有浆细胞分化,14.8%血管丰富、含有成片印戒样细胞,8.3%见坏死,3.7%见嗜酸细胞、硬化带。CB中44.2%CD10、48.1%bcl-6阳性,2例ALCL均阳性,而3例IB均阴性。结论:各变型有B细胞淋巴瘤共有的病理组织学特点,又有其各自的病理特征;CD10/bCL-6表达在识别变型中有重要意义。 Objective: To study histopathologic features and immunophenotype of morphologic variants of DLBCL. Methods: A total of 108 cases with DLBCL were studied and immunohistochemical staining was carried out for CD10/bcl-6 in DLBCL tissue microarry. Results: Morphologic variants of the 108 cases were shown as follows: 89.9% centroblastic, 2.8% immunoblastic, 1.9% anaplastic large B-cell type, 1.9% T cell rich B cell type and 3.7% others. The cases with DLBCL indicated the rich reactive cell in 23.1%, fibrillary matrix in 41.7%, plasmacytic differentiation in 21.3%, rich blood ves- sel in 14.8%, signet ring cells in 14.8%, necrosis in 8.3%, eosinophils in 3.7% and bands of sclerosis in 3.7%. Fibrillary matrix and rich reactive cell were frequently seen in any of variants. CD10 and bcl- 6 was positive in 44.2%, 48.1% of CB and in 2/2 cases with ALCL, respectively, but negative in 3/3 IB. Conclusions: DLBCL variants have similar and special histopsthology features of B cell lymphoma. CD10/BCL-6 expression pattern may be helpful in identifying main variants of DLBCL.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2006年第3期141-144,共4页 Chinese Journal of Clinical Oncology
基金 广东省社会发展攻关基金(编号:B30301) 广州市科技计划基金资助(编号:2002Z34061)
关键词 DLBCL 组织病理学 免疫表型 Diffuse large B-cell lymphoma Histopathology Immunophenotype
  • 相关文献

参考文献10

  • 1Osterman B, Cavallin-Stahl E, Hagberg H, et al. High-grade non-Hodgkin's lymphoma stage Ⅰ. A retrospective study of treatment, outcome and prognostic factors in 213 patients[J]. Acta Oncol, 1996, 35(2):171-177.
  • 2Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumors of haematopoietic and lymphoid tissues[M]. IARC, Lyon,France, 2001.171.
  • 3Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma[]]. Blood, 2002, 99(4):1136-1143.
  • 4Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study[l]. Clha Cancer Res, 2003, 9(2):722- 728.
  • 5Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J]. Blood, 2004,103(1):275-282.
  • 6Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma[J]. AmJ Surg Pathol, 2004, 28(4):464-470.
  • 7陶琨,朱雄增,徐薇苓,陈忠伟,陆洪芬.弥漫性大B细胞淋巴瘤的临床病理和免疫组织化学特征[J].中华病理学杂志,2002,31(2):112-115. 被引量:24
  • 8Gatter K and Delsol G. Atlas: The diagnosis of lymphoproliferative diseases [M] (chapter 13)[M]. Oxford University Press. New YorK, 2002.
  • 9Ree HJ, Yang WI, Kim CW, et al. Coexpression of Bd-6 and CD10 in diffuse large B-ceU lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma[J]. Hum Pathol, 2001, 32(9):954-962.
  • 10Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma [J]. Blood, 2003, 101(1):78-84.

二级参考文献9

  • 1Osterman B, Cavallin-Stahl E, Hagberg H, et al. High-grade non-Hodgkin′s lym phoma stage I. A retrospective study of treatment, outcome and prognostic factor s in 213 patients. Acta oncol,1996,35:171-177.
  • 2Harris NL,Jaffe ES, Diebold J et al. The World Health Organi zation classification of neoplastic diseases of the haematopoietic and lymphoid tissue. Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology,2000, 36:69-86.
  • 3Lennert K, Feller AC. Histopathology of non-Hodgkin′s lymph oma (based on the updated Kiel classification ).Berlin:Springer-Verlag, 1992.
  • 4Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL -6 gene in diffuse large cell non-Hodgkin′s lymphoma. Blood, 1994,83:1757-1759.
  • 5Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl- 6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med, 1994, 331:74 -80.
  • 6Flenghi L,Ye BH, Fizzotti M, et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am J Pathol ,19 95,147:405-411.
  • 7Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finge r-encoding gene, BCL-6,in diffuse large-cell lymphoma. Science, 1993,262:74 7-750.
  • 8Flenghi L, Bigerna B, Fizzotti M ,et al. Monoclonal antibodi es PG-B6a and PG-B6p recognize, respectively, a highly conserved and formol-resistant epitope on t he human BCL-6 protein amino-terminal region. Am J Pathol ,1996,148:1543-1555 .
  • 9Carbone A, Gloghini A,Gaidano G, et al. BCL-6 protein expressi on in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood , 1997,90:2445-2450.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部